Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. - Wikidata - wikimedia - TriplyDB

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.

http://www.wikidata.org/entity/Q36397083

about

A look at autoimmunity and inflammation in the eye Emerging drugs for uveitis Cellular targeting in autoimmunity Application of IL-2 therapy to target T regulatory cell function Daclizumab therapy for multiple sclerosis The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy Retinopathies associated with antiretinal antibodies An anti-interleukin-2 receptor drug attenuates T- helper 1 lymphocytes-mediated inflammation in an acute model of endotoxin-induced uveitis The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.Daclizumab treatment for multiple sclerosis.Determination of Genes Related to Uveitis by Utilization of the Random Walk with Restart Algorithm on a Protein-Protein Interaction Network.Management of chronic uveitis.Immunopathogenesis of ocular Behçet's disease High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.Advances in interleukin 2 receptor targeted treatment Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases.Pharmacotherapy for uveitis: current management and emerging therapy.Immunotherapeutic strategies in autoimmune uveitis Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.Developments in the treatment of uveitis.IL-27-induced modulation of autoimmunity and its therapeutic potential.Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta Management of uveitis: a rheumatologic perspective.Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.Immunotherapy for ovarian cancer: what's next?An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.Cytokines in immunotherapy of experimental uveitis.Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.Recent developments in the pharmacological treatment and prevention of corneal graft rejection.The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Cytokine-based immunointervention in the treatment of autoimmune diseases.Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease Suppressor of cytokine signaling-1 (SOCS1) inhibits lymphocyte recruitment into the retina and protects SOCS1 transgenic rats and mice from ocular inflammation.Cytokines in autoimmune uveitis.Associations of Independent IL2RA Gene Variants with Intermediate Uveitis Clinical trials in noninfectious uveitis Autoreactive memory CD4+ T lymphocytes that mediate chronic uveitis reside in the bone marrow through STAT3-dependent mechanisms.A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease Biological response modifier therapy for refractory childhood uveitis.

P2860

Q24623065-D636E0A5-A749-45AA-91DE-FDED8D1570C5 Q24630848-BC7A20AA-03AA-4AAD-AA1B-BEC3911CBE58 Q26824580-55863EC6-FDD1-4790-9C0D-CDA794697C74 Q26827327-FB75AA8B-87AB-43ED-8903-08B9040581B9 Q27022517-B98C2C8B-B253-47B7-A9E6-91356F7973E5 Q28088784-1A88D4B7-F694-4BC5-ABB9-A4862C51957C Q28347225-D0BB2021-C452-4DCC-8330-EF1B1F7EE45D Q28540312-EA13FBFD-4BBA-4084-819D-46D9438D78B4 Q30730505-95B0390B-7A1D-4F66-9FB0-FCE2FB342972 Q33382919-B51DE6AC-5A06-4A79-AC8A-65A44960D296 Q33755275-C8FB9804-5569-4F75-A0C7-9791F4AEF088 Q33846063-B8F0A409-DB36-4C56-BCAE-DACF47F141CF Q33908937-95217519-C03B-4571-9260-667EBDC65E4B Q34070773-55C5C3BC-C25D-49BE-B7B9-B9449B505A89 Q34071328-4FA71389-1E33-48F9-A2B5-11084891C1EE Q34240839-371A9094-2652-4527-9B72-C8D53571D029 Q34274075-089FCAA0-1E63-4353-8BB3-193D23D42789 Q34274950-0C4F8AEC-8F3C-4472-939C-32A11215F90C Q34409257-56C91045-0685-4B6F-B955-EF5C1E330AE5 Q34481964-B261284C-E124-4B96-97C9-D9EB2384D67D Q34488727-F042AD6E-C9B7-4D0B-A329-CCE71F30C25C Q34514715-4CFA71F9-81C9-49B9-8B2F-32D3316FE59F Q34526831-B0726394-E00E-4149-9216-97BC6AC7CBC4 Q34596171-CE36E0F4-66F4-4F48-BD28-066BC6F0F6E3 Q34743514-1C56F62B-A5D0-4D05-85A3-DD5051B73411 Q34893862-657BC20E-74C6-4275-B07E-E2DDCCA6F19C Q34949098-7F9CE961-1D22-40E1-9D72-B88B1F8C8D6D Q34993224-B17A9535-2CF3-40F1-B68E-11C6FC443055 Q35012335-A9E98663-50A9-4252-A252-FBC6662534DA Q35040789-89439D6B-6F9E-40B9-B7B2-FA728A5F8006 Q35058213-2AFDB09F-8A7D-4CCF-AAF1-1437A588183F Q35109131-B58D3B94-B87D-45F8-ACE1-3BB7808D5090 Q35215459-28F77A42-FFA0-4CE2-B0E7-C82D8A145AC4 Q35221160-0D8578D8-47FD-457F-9F8F-58C675A92BC3 Q35294461-36D9CB8E-73AF-4232-BCD0-C4794D833D93 Q35680408-3413C5D0-BA21-4C6C-8E08-DB2BE6F4D5F8 Q35681664-B052553C-DE6C-4097-A185-A0DE9A3FAFDF Q35831317-1A6DB973-4BEC-451D-8175-A465E9895178 Q35945533-259FE414-5C3D-4D3B-BF87-6166ED6601B8 Q36025876-72A7E430-3C45-4060-8402-61F1CDDF87F1

P2860

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.

http://www.wikidata.org/entity/Q36397083

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh

1999年學術文章

@zh-hant

name

Treatment of noninfectious int ...... : a phase I/II clinical trial.

@ast

Treatment of noninfectious int ...... : a phase I/II clinical trial.

@en

type

label

Treatment of noninfectious int ...... : a phase I/II clinical trial.

@ast

Treatment of noninfectious int ...... : a phase I/II clinical trial.

@en

prefLabel

Treatment of noninfectious int ...... : a phase I/II clinical trial.

@ast

Treatment of noninfectious int ...... : a phase I/II clinical trial.

@en

P1433

Q36397083-281738D8-063E-415F-B569-365F4D80A10C

P1476

Q36397083-07B4D4C3-2444-4F2A-B25C-94832E0EFD53

P2093

Q36397083-1F388721-F325-477E-A113-C3AED8E490CD

Q36397083-20F8DECC-4D2F-422D-8735-2C542F7FAC1E

Q36397083-3E291E5C-FCFF-43B9-89CE-DE628F8065F9

Q36397083-45AF76AD-3455-4154-9C6C-C25C9FA11034

Q36397083-46D84B28-5066-40FD-AF27-BEBD34274965

Q36397083-9360935A-42FF-445D-AFF7-9BB6B8712E05

Q36397083-9BEFABE0-6DA5-49BC-98B5-6A6E7BAF8A90

Q36397083-9C17D5AF-AC8F-4FC5-B3D5-675342D26443

Q36397083-C1ADAC72-E47C-4FA2-A3B6-D00AC37AFD4F

Q36397083-CD35C1E2-BE66-4488-9580-C77B1EE94706

P2860

Q36397083-009223CD-A383-456B-9AD6-C6B0E4D8E2C6

Q36397083-093AE41F-B509-4289-BF59-EFD1AD594833

Q36397083-1410B319-7D05-41F7-89B3-FD0AD1EC3548

Q36397083-971011D9-DF88-44BD-ABB7-67B1BFD23A78

Q36397083-A289C981-7AB2-43A8-8D6A-AAC814F3E4EF

P304

Q36397083-AA971EAA-2AE4-4670-9232-82F123AA7B63

P31

Q36397083-70487846-7FF5-4D46-887E-C70DC5DC6563

P356

Q36397083-FEF15B08-D76A-411E-80E0-99B85D312FA4

P407

Q36397083-7E374299-2E39-41E7-9B5D-55C65D224F63

P433

Q36397083-37B5C726-9755-4A61-B701-3450943E2B2A

P478

Q36397083-809FD594-5244-409A-AD9D-F423484AF343

P577

Q36397083-3B15B788-9662-4CE9-A707-1D25FA92F155

P5875

Q36397083-0D2A34C4-7D12-4243-8CB5-8B1A50F6ADF8

P698

Q36397083-03B3BA3C-CEEE-4F3C-890D-34B117E2D248

P921

Q36397083-3DCFB359-A4E9-40B3-8ACC-EBB4A033D415

Q36397083-44346019-8F7F-4961-831F-91755D9C76BE

Q36397083-FDF2CE99-27F1-4ED2-B65B-3DBDDB9EE207

P932

Q36397083-2E2E4C3D-B1F5-4E2C-8CEC-EDD37A6EA590

P356

PNAS.96.13.7462

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Treatment of noninfectious int ...... : a phase I/II clinical trial.

@en

P2093

A Yaffe

http://www.w3.org/2001/XMLSchema#string

C K Goldman

http://www.w3.org/2001/XMLSchema#string

E Fortin

http://www.w3.org/2001/XMLSchema#string

J Smith

http://www.w3.org/2001/XMLSchema#string

L Rizzo

http://www.w3.org/2001/XMLSchema#string

P Sran

http://www.w3.org/2001/XMLSchema#string

P Van Veldhuisen

http://www.w3.org/2001/XMLSchema#string

R B Nussenblatt

http://www.w3.org/2001/XMLSchema#string

R Schiffman

http://www.w3.org/2001/XMLSchema#string

S M Whitcup

http://www.w3.org/2001/XMLSchema#string

P2860

Longitudinal data analysis for discrete and continuous outcomes

Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications.

Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation.

Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases

T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat

P304

7462-7466

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.96.13.7462

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

1999-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12922547

http://www.w3.org/2001/XMLSchema#string

P698

10377437

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial

P932

22108

http://www.w3.org/2001/XMLSchema#string